At the Virtual ACCC Annual Meeting & Cancer Center Business Summit, experts convened to discuss real-world experiences and challenges associated with the pandemic.
At the Virtual ACCC Annual Meeting & Cancer Center Business Summit, a panel of healthcare professionals discussed real-world experiences on the challenges of COVID-19 and its effect on cancer care.
True or False: According to neoteric research, cytotoxic chemotherapy treatment was not associated with adverse COVID-19 outcomes.
The FDA has approved daratumumab plus hyaluronidase combined with bortezomib, cyclophosphamide, and dexamethasone (VCd) for patients with newly-diagnosed AL amyloidosis.
Study data show that although cytotoxic chemo is not tied to adverse COVID-19 outcomes, hematologic and lung malignancies, lymphopenia, and neutropenia are.
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
Findings from a cohort study of patients with advanced or metastatic CRC showed that increased coffee consumption was linked to a lower risk for disease progression and death.
Survey responses from adult cancer survivors underscore the need for improved survivorship care models that involve integrated care and a smoother transition from therapy.
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.